Instead of gossypol treatment, the combination of the loss of ALDH1L1 deletion and phenformin treatment decreased tumor growth in an in vivo KRAS-driven lung cancer model, and the synergy correlated with a decrease in ATP production [19]. Here, KRAS is linked to lung cancer.